No title
Objectives: To examine the accessibility and quality of drug company payment data in Europe.Design: Comparative policy review of payment data in countries with different regulatory approaches to disclosure.Setting; 37 European countries.Participants: European Federation of Pharmaceutical Industries and Associations, its trade group and their drug company members; eurosfordocs.eu, an independent da
